Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblings
Authors:
- Nobuo SakuraNSNobuo Sakura
- Motomichi KosugaMKMotomichi Kosuga
- Torayuki OkuyamaTOTorayuki Okuyama
- Masao KobayashiMKMasao Kobayashi
- 1 March 2013
- journal article
- case report
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (3) , 172-177
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3‐year follow‐upActa Paediatrica, 2011
- Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end pointsJournal of Inherited Metabolic Disease, 2011
- Expression of the disease on female carriers of X-linked lysosomal disorders: a brief reviewOrphanet Journal of Rare Diseases, 2010
- Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)Molecular Genetics and Metabolism, 2010
- Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantationMolecular Genetics and Metabolism, 2009
- Idursulfase for the treatment of mucopolysaccharidosis IIExpert Opinion on Pharmacotherapy, 2008
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyEuropean Journal of Pediatrics, 2007
- Mucopolysaccharidosis type II in females: Case report and review of literaturePediatric Neurology, 2005
- Double-strand breaks may initiate the inversion mutation causing the Hunter syndromeHuman Molecular Genetics, 1997
- Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase geneHuman Mutation, 1993